CENTENNIAL, CO
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Allosource, founded in 1994, is a major nonprofit in the Health Care sector that reported $172.7M in total revenue in fiscal year 2023. Revenue grew 10% year-over-year, indicating healthy expansion.
INSPIRED BY THE GIFT OF DONATION FROM OUR COMMUNITIES, ALLOSOURCE RESPONSIBLY PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING.
PROCESSING AND DISTRIBUTION: WITH THE GIFT OF DONATED TISSUE, ALLOSOURCE PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. IN 2023, ALLOSOURCE FULFILLED THIS...
PROCESSING AND DISTRIBUTION: WITH THE GIFT OF DONATED TISSUE, ALLOSOURCE PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. IN 2023, ALLOSOURCE FULFILLED THIS RESPONSIBILITY BY PROCESSING MORE THAN 8,300 DONORS, AND DISTRIBUTED THE TISSUE THROUGHOUT NORTH AMERICA, SOUTH AMERICA, CARIBBEAN, EUROPE, MIDDLE EAST, ASIA AND OCEANIA. MUSCULOSKELETAL AND SOFT TISSUE DONORS PROVIDE AN OPPORTUNITY TO CREATE LIFE-SAVING AND LIFE-ENHANCING SOLUTIONS IN ORTHOPEDIC, SPINE, BURN, AND WOUND PROCEDURES TO HELP RESTORE PATIENT HEALTH AND MOBILITY. ALLOSOURCE IS ACCREDITED BY THE AMERICAN ASSOCIATION OF TISSUE BANKS AND IS REGISTERED WITH THE FDA.
RESEARCH, EDUCATION, AND TRAINING: ALLOSOURCE IS DEDICATED TO ADVANCING THE USE OF TRANSPLANTABLE ALLOGENEIC CELLS AND TISSUE THROUGH PIONEERING RESEARCH. IN 2023, ALLOSOURCE CONTINUED ITS RESEARCH...
RESEARCH, EDUCATION, AND TRAINING: ALLOSOURCE IS DEDICATED TO ADVANCING THE USE OF TRANSPLANTABLE ALLOGENEIC CELLS AND TISSUE THROUGH PIONEERING RESEARCH. IN 2023, ALLOSOURCE CONTINUED ITS RESEARCH IN THE AREAS OF PEDIATRIC ORTHOPEDICS AND CELLULAR THERAPIES, EXPANDING THE IMPACT OF DONATION BY FINDING ADDITIONAL USES FOR TISSUE. ALLOSOURCE WORKED WITH THE 501(C)(3) ORGANIZATIONS THAT RECOVER TISSUE TO REDUCE TISSUE CONTAMINATION. WE ALSO PROVIDED EDUCATIONAL OPPORTUNITIES TO OUR PARTNER ORGAN PROCUREMENT ORGANIZATIONS TO HELP THEM INCREASE DONATION RATES IN THEIR RESPECTIVE COMMUNITIES.
CHARITABLE CONTRIBUTION ACTIVITY: IN ALIGNMENT WITH OUR MISSION, ALLOSOURCE PROVIDED GRANTS TO SUPPORT 501(c)(3) ORGANIZATIONS THAT ARE INVOLVED IN ORGAN, EYE, AND TISSUE DONATION, S.T.E.M...
CHARITABLE CONTRIBUTION ACTIVITY: IN ALIGNMENT WITH OUR MISSION, ALLOSOURCE PROVIDED GRANTS TO SUPPORT 501(c)(3) ORGANIZATIONS THAT ARE INVOLVED IN ORGAN, EYE, AND TISSUE DONATION, S.T.E.M. EDUCATION, AS WELL AS PATIENT PHYSICAL AND MENTAL HEALING. IN 2023, ALLOSOURCE GAVE GRANTS TO THREE ORGANIZATIONS TO FURTHER TISSUE DONATION AND TRANSPLANTATION AWARENESS AND PROCESSES, AND MADE CHARITABLE CONTRIBUTIONS TO ELEVEN OTHER 501(C)(3) ORGANIZATIONS THROUGH DIRECT AND MATCHING EMPLOYEE FINANCIAL DONATIONS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $172,749,079 | $157,659,866 | +0.1% |
| Expenses | $173,901,699 | $164,951,555 | +0.1% |
| Net Income | $-1,152,620 | $-7,291,689 | -0.8% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| N/A | PRESIDENT, CEO AS OF 1/9/23 | 40.0 |
Officer
Director
|
$509,715 | $54,366 | $564,081 |
| N/A | BOARD MEMBER - CHAIR | 3.0 |
Officer
Director
|
$0 | $0 | $0 |
| N/A | BOARD MEMBER - VICE CHAIR | 3.0 |
Officer
Director
|
$0 | $0 | $0 |
| N/A | BOARD MEMBER - TREASURER | 3.0 |
Officer
Director
|
$0 | $0 | $0 |
| N/A | PRESIDENT, CEO UNTIL 1/9/23 STRATEGIC ADVISOR 1/10/23-12/29/23 | 30.0 |
Officer
Director
|
$1,423,126 | $157,274 | $1,580,400 |
| N/A | BOARD MEMBER | 3.0 |
Director
|
$0 | $0 | $0 |
| N/A | BOARD MEMBER | 3.0 |
Director
|
$0 | $0 | $0 |
| N/A | CHIEF COMMERCIAL OFFICER | 40.0 |
Officer
|
$401,804 | $56,775 | $458,579 |
| N/A | CHIEF FINANCIAL OFFICER | 40.0 |
Officer
|
$436,805 | $52,795 | $489,600 |
| N/A | VP INTERNATIONAL | 40.0 |
Key Emp
|
$230,004 | $43,719 | $273,723 |
| N/A | SVP OPERATIONS | 40.0 |
Key Emp
|
$396,268 | $41,825 | $438,093 |
| N/A | SVP QUALITY & PERFORMANCE EXCELLENCE | 40.0 |
Key Emp
|
$325,993 | $50,367 | $376,360 |
| N/A | SVP HUMAN RESOURCES | 40.0 |
Key Emp
|
$316,827 | $36,008 | $352,835 |
| N/A | SR DIRECTOR PRODUCT DEVELOPMENT INNOVATION & CLINICAL AFFAIRS | 40.0 |
Highest
|
$305,168 | $41,499 | $346,667 |
| N/A | EXECUTIVE DIRECTOR ESSENT BIOLOGICS | 40.0 |
Highest
|
$495,339 | $18,097 | $513,436 |
| N/A | MEDICAL DIRECTOR | 40.0 |
Highest
|
$234,667 | $23,785 | $258,452 |
| N/A | ASSOCIATE MEDICAL DIRECTOR | 40.0 |
Highest
|
$226,999 | $22,420 | $249,419 |
| N/A | REGIONAL ACCOUNTS MANAGER - RECONSTRUCTION | 40.0 |
Highest
|
$223,302 | $22,360 | $245,662 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $172,749,079 | $173,901,699 | $152,171,181 | $-1,152,620 |
| 2022 | $157,659,866 | $164,951,555 | $151,465,252 | $-7,291,689 |
| 2021 | $155,893,092 | $149,970,189 | $159,280,859 | $5,922,903 |
| 2020 | $137,184,154 | $142,008,508 | $155,465,890 | $-4,824,354 |
| 2019 | $146,066,508 | $141,353,159 | $159,803,280 | $4,713,349 |
| 2018 | $162,715,599 | $153,235,852 | $149,573,472 | $9,479,747 |
Compare Allosource with other nonprofits in Colorado and across the country.